(Press-News.org) ATS 2013, PHILADELPHIA ─ A small, easily implantable device called the Lung Volume Reduction Coil (LVRC) may play a key role in the treatment of two types of emphysema, according to a study conducted in Europe. Results of the study indicate the beneficial effects of the device persist more than a year after initial treatment.
The study will be presented at the ATS 2013 International Conference.
"LVRC treatment results in significant and clinically relevant improvements in lung function, ability to exercise and quality of life for patients with emphysema," said Gaetan Deslee, MD, PhD, professor of respiratory medicine at the University Hospital of Reims, France. "Our study shows the device is effective in treating both homogeneous disease, where emphysema is distributed evenly throughout the lungs, and heterogeneous disease, where emphysema is isolated to specific areas of the lungs."
The coil works by gathering and compressing diseased lung tissue, allowing healthy tissue to function more efficiently. The device is implanted in a simple procedure which does not require a surgical incision. Patients typically are implanted with multiple devices in each affected lung, with each lung being treated in a separate procedure.
The study's researchers gathered and analyzed data from three nearly identical multicenter European studies that analyzed the safety and efficacy of LVRC treatment in 109 patients with severe emphysema who had received two separate coil treatments. In total, 2081 devices were implanted in 218 procedures. In addition, computed tomography (CT) scans were used to determine whether these patients had homogeneous or heterogeneous disease.
Follow-up data were gathered from each patient at six months and 12 months following the procedure on the second lung. To evaluate the effectiveness of the LVRC device, the studies used a validated quality of life survey designed for patients with obstructive airways disease and three other standard measures: the forced expiratory volume or FEV1, which measures the maximum amount of air that can be exhaled in one second; the residual volume or RV, which measures the volume of air remaining in the lungs after a maximal exhalation; and six-minute walking distance or 6WMD, which estimates a person's ability or capacity to exercise.
The study authors found that, at both six months and 12 months following the procedure, values for all four measurements were significantly improved.
"The results clearly demonstrate that a broad population of emphysema patients can achieve clinically and statistically significant improvements in quality of life, exercise capacity and lung function from treatment with LVRC, and that these improvements are sustained at one year from treatment," Dr. Deslee said.
There were few adverse events. Following 218 procedures, there were 13 exacerbations of chronic obstructive pulmonary disease (COPD), nine incidents of pneumonia and nine cases of pneumothorax (deflated lung); in addition, one patient developed a cough containing significant amounts of blood (haemoptysis). All of these events resolved with standard care.
A post-hoc analysis of 53 patients identified as having either homogeneous or heterogeneous disease showed the improvements from LVRC treatment were similar between the groups, an important finding since other minimally-invasive treatment methods have not shown sustained efficacy in the many patients who have diffuse patterns of emphysema, Dr. Deslee noted.
Emphysema and chronic bronchitis are the two primary forms of COPD, recognized worldwide as a major public health concern.
"Emphysema is a progressive disease and there is no known cure," Dr. Deslee said. "Because available drug and behavior-based therapies have only limited effectiveness in relieving the symptoms of the disease, researchers have pinned much hope on the emergence of new medical implants which seek to provide significant and lasting improvements in patients' lung function and ability to perform activities of daily living. To date, many of these technologies have come up short, and data on the sustained effectiveness of new technologies is scarce."
The U.S. Food and Drug Administration (FDA) recently gave its approval for a clinical study evaluating the LVRC in emphysema patients, the first step in making the technology available to emphysema patients in the United States. The LVRC has also been selected by the French Ministry of Health for a national cost-effectiveness study, expected to lead to reimbursement of the treatment for emphysema patients in France.
"A minimally-invasive technology which proves to be effective in treating a large population of emphysema patients could potentially help patients to live healthier lives despite their emphysema," Dr. Deslee said. "Because the disease imposes such an enormous economic and social burden, rapid adoption of such a technology could change the paradigm of emphysema management, evolving the standard of care from today's drug and behavior-based methods to include routine use of treatment procedures to optimize and prolong a patient's overall health."
###
* Please note that numbers in this release may differ slightly from those in the abstract. Many of these investigations are ongoing; the release represents the most up-to-date data available at press time.
Abstract 39749
Lung Volume Reduction Coil (LVRC) Sustained Treatment Effectiveness In Heterogeneous And Homogenous Emphysema
Type: Scientific Abstract
Category: 09.08 - COPD: Non-Pharmacological Treatment (CP)
Authors: G. Deslee1, S. Blaas2, W. Gesierich3, F.J. Herth4, J. Hetzel5, R. Kessler6, C.H. Marquette7, M. Pfeifer2, F. Stanzel8, C. Witt9, D.-J. Slebos10; 1University Hospital of Reims - Reims/FR, 2Klinikum Donaustauf - Donaustauf/DE, 3Asklepios - Gauting - Gauting/DE, 4Thorax Klinik - Heidelberg/DE, 5UKT University Hospital - Tuebingen/DE, 6University Hospital Strasbourg - Strasbourg/FR, 7University Hospital Nice - Nice/FR, 8Lungenklinik - Hemer/DE, 9Charité Universitätsmedizin Berlin - Berlin/DE, 10University Medical Center Groningen - Groningen/NL
Abstract Body
Rationale: The Lung Volume Reduction Coil (LVRC, PneumRx Inc.) is a bronchoscopic device for the treatment of severe emphysema. Three multicenter European studies with nearly identical protocols have analyzed the safety and efficacy of LVRC treatment in severe emphysema. The results of these studies out to 15 months post-treatment, including sub-group efficacy analysis, will be presented.
Methods: To date, 109 patients (mean age: 61 years, mean FEV1: 29%, mean RV: 242%) were treated by bilateral LVRC performed in two separate procedures in two contralateral lobes, with follow-up beyond one year. Data was analyzed at 6-months and 12-months post treatment. A post-hoc blinded CT analysis was performed on a subset of data i) by a digital lobar CT emphysema score assessing the percentage destruction below -950HU with a END
Tiny, implantable coil promises hope for emphysema patients
2013-05-21
ELSE PRESS RELEASES FROM THIS DATE:
Exposure to traffic pollution increases asthma severity in pregnant women
2013-05-21
ATS 2013, PHILADELPHIA ─ Air pollutants from traffic are associated with increased asthma severity levels in pregnant asthmatic women, according to a new study.
"Air pollution is a known trigger for asthma symptoms," said lead author Janneane Gent, PhD, Research Scientist in Epidemiology (Environmental Health) at the Yale School of Public Health. "In our study, exposures were assessed using a sophisticated air pollution modeling system (Community Multiscale Air Quality, CMAQ) that permits community-level estimates (i.e., close to where the subject resides) instead ...
Study finds air pollution and noise pollution increase cardiovascular risk
2013-05-21
ATS 2013, PHILADELPHIA ─ Both fine-particle air pollution and noise pollution may increase a person's risk of developing cardiovascular disease, according to German researchers who have conducted a large population study, in which both factors were considered simultaneously.
"Many studies have looked at air pollution, while others have looked at noise pollution," said study leader Barbara Hoffmann, MD, MPH, a professor of environmental epidemiology at the IUF Leibniz Research Institute for Environmental Medicine in Germany. "This study looked at both at the same ...
Prenatal exposure to traffic is associated with respiratory infection in young children
2013-05-21
ATS 2013, PHILADELPHIA ─ Living near a major roadway during the prenatal period is associated with an increased risk of respiratory infection developing in children by the age of 3, according to a new study from researchers in Boston.
"The connection between in utero and early life cigarette smoke exposure and adverse infant respiratory outcomes is well-established, but the relation of prenatal ambient air pollution to risk of infant respiratory infection is less well-studied," said lead author Mary Rice, MD, a pulmonary and critical care fellow at Massachusetts ...
Early childhood respiratory infections may explain link between analgesics and asthma
2013-05-21
ATS 2013, PHILADELPHIA ─ A new study conducted by Boston researchers reports that the link between asthma and early childhood use of acetaminophen or ibuprofen may be driven by underlying respiratory infections that prompt the use of these analgesics, rather than the drugs themselves.
The results of the new study will be presented at the ATS 2013 International Conference.
Analgesics like ibuprofen and acetaminophen are routinely given to treat fever in infants, and several studies have shown a link between the use of analgesics during infancy and the subsequent ...
Combined wood and tobacco smoke exposure increases risk and symptoms of COPD
2013-05-21
ATS 2013, PHILADELPHIA ─ People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease (COPD) and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according to the results of a new population-based study conducted by researchers in Colombia.
The results of the study will be presented at the ATS 2013 International Conference.
"Although previous studies have shown ...
May/June 2013 Annals of Family Medicine tip sheet
2013-05-21
Much of the May/June 2013 issue of Annals of Family Medicine and the entirety of an accompanying supplement published in partnership with the U.S. Agency for Healthcare Research and Quality are about changing primary care practice. Practice transformation on a large scale toward the patient-centered medical home model of care is a cornerstone of health care reform efforts in the United States, and the research and commentary in this issue can serve as a roadmap to achieve practice transformation. Not only do the articles address the opportunities, challenges, costs, processes ...
Whole-cell vaccine was more effective than acellular vaccine during California pertussis outbreak
2013-05-21
OAKLAND, Calif., May 20, 2013 — Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.
Whole-cell pertussis vaccines, also called DTwP, were available from the 1940s to 1990s, but were associated with safety concerns that ultimately led to the development of acellular pertussis vaccines, which are also called DTaP. By the late 1990s, the United States had switched from whole-cell to acellular vaccines for all ...
Principles of locomotion in confined spaces could help robot teams work underground
2013-05-21
Future teams of subterranean search and rescue robots may owe their success to the lowly fire ant, a much-despised insect whose painful bites and extensive networks of underground tunnels are all-too-familiar to people living in the southern United States.
By studying fire ants in the laboratory using video tracking equipment and X-ray computed tomography, researchers have uncovered fundamental principles of locomotion that robot teams could one day use to travel quickly and easily through underground tunnels. Among the principles is building tunnel environments that ...
Intestinal bacteria protect against E. coli O157:H7
2013-05-21
A cocktail of non-pathogenic bacteria naturally occurring in the digestive tract of healthy humans can protect against a potentially lethal E. coli infection in animal models according to research presented today at the 113th General Meeting of the American Society for Microbiology. The research, conducted by scientists at the University of Michigan Medical School in Ann Arbor, could have important implications for the prevention or even treatment of this disease.
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a food-borne pathogen that has been responsible for ...
Leading explanations for whooping cough's resurgence don't stand up to scrutiny
2013-05-21
ANN ARBOR—Whooping cough has exploded in the United States and some other developed countries in recent decades, and many experts suspect ineffective childhood vaccines for the alarming resurgence.
Some say the vaccine wears off quicker than public health officials had previously believed. Others suggest that the vaccine protects against illness but does not prevent transmission of the bacterial disease, which is also known as pertussis.
But a University of Michigan-led research team has concluded that neither of these proposed mechanisms for the resurgence of pertussis ...